Recently, the Category 1 innovative drug Pegmolesatide Injection (Chinese trade name: 圣罗莱) of Jiangsu Hansoh Pharmaceutical Group Company Limited is approved by China NMPA. The drug is indicated to treat anemia in chronic kidney disease (CKD) adult patients who have not received erythropoiesis-stimulating agents (ESA) and not on dialysis; as well as who are receiving short-acting erythropoietintreatment and on dialysis (this drug is not for use as a substitute for red blood cell transfusions in patients who need immediate treatment for anemia).

　　Pegmolesatide is a long-acting peptide-based ESA, which promotes the proliferation of red blood cells in the body and improves anemia and related symptoms in patients with CKD. The approval of this drug provides a new treatment option for CKD patients with anemia.